文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 维卡格雷 Vicagrel
侵权投诉

维卡格雷 Vicagrel

JMC维卡格雷设计合成

维卡格雷 Vicagrel

OvercomingClopidogrelResistance:DiscoveryofVicagrelasaHighlyPotentandOrallyBioavailableAntiplateletAgent

JiaqiShan, , BoyuZhang, , YaoqiuZhu,§BoJiao,∥WeiyiZheng,⊥XiaoweiQi,#FushengLv,#andHongbinSun*, ,

YanchunGong, , FangYuan,#

StateKeyLaboratoryofNaturalMedicinesand CenterofDrugDiscovery,CollegeofPharmacy,ChinaPharmaceuticalUniversity,24TongjiaXiang,Nanjing210009,China§

MetabQuestResearchandConsulting,1720OakAvenue,Suite403,Evanston,Illinois60201,UnitedStates∥

DepartmentofPharmacology,SchoolofPharmacy,ShandongUniversity,44WenhuaWestRoad,Jinan250012,China⊥

ConcordPharmatechCo.,Ltd.,9XinglongRoad,Nanjing211800,China#

JiangsuVcarePharmaTechCo.,Ltd.,15WanshouRoad,Nanjing211800,China

*

SupportingInformationClopidogrel(1)(Figure1)isanoralantiplateletagentusedtodiphosphate(ADP)receptorsontheplateletmembrane.Itisapreventbloodclotsincoronaryarterydisease,peripheralprodrugrequiringtwo-stepmetabolicconversionbythevasculardisease,andcerebrovasculardisease.Currently,dualcytochromeP450(CYP)systemtogenerateclopidogrelactivetreatmentwithaspirinandclopidogrelisthecornerstoneofmetabolite(AM,5)viaclopidogrelthiolactone(4a)(Schemeantiplatelettherapyforpatientswithacutecoronarysyndrome1).2However,nonresponsivenessorpoorresponsivenessto(ACS)andpreventionofthromboticeventsafterpercutaneousclopidogreltherapyoccursinupto30%ofCaucasianpatientscoronaryintervention(PCI)withstenting.1Thedrugworksby

(~2%arepoormetabolizers(PMs),~26%areintermediatemetabolizers(IMs)),3especiallyinPMscarryingCYP2C192*loss-of-functionpolymorphism,leadingtolowerlevelsoftheactivemetaboliteofclopidogrel,lessinhibitionofplatelets,anda1-to5-foldhigherriskfordeath,myocardialinfarction,andstrokeincomparisonwithnoncarriers.4,5Thisreferstotheconceptofclopidogrelresistance(CR).In2010,theFDAputablackboxwarningonclopidogreltomakepatientsandhealthcareprofessionalsawarethatCYP2C19PMsareathighriskoftreatmentfailure.Currently,clinicalpracticetoovercomeCRincludes(1)theadjunctiveuseofcilostazol,(2)increasingthedoseofclopidogrel,(3)theuseofnewantiplateletagents,suchasprasugrel(2)andticagrelor(3)(Figure1).6However,theaboveapproachesmayincreasetheriskofmajor7andfatalbleedingsandreducepatientcompliance.Takentogether,therearestillunmetmedicalneedsforthetreatmentofACSanditscomplications,especially

Figure1.StructuresofP2Y12receptorantagonists.

维卡格雷 Vicagrel

Received:January10,2012Published:March19,

维卡格雷 Vicagrel

2012

第1页

你可能喜欢

热门文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email